BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Adlyxin / Lyxumia (lixisenatide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Adlyxin / Lyxumia (lixisenatide)\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07173712-128@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Adlyxin / Lyxumia (lixisenatide): Phase 4 readout est. (NCT07173712
 )
DESCRIPTION:Adlyxin / Lyxumia (lixisenatide)\, phase 4\, Type 2 Diabetes.\n
 Study: Regimen Transition After Short-Term Intensive Insulin Therapy in Ty
 pe 2 Diabetes\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lixisenatide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07173712
URL:https://assetmemo.bio/drug/lixisenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07307235-128@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Adlyxin / Lyxumia (lixisenatide): Phase 4 readout est. (NCT07307235
 )
DESCRIPTION:Adlyxin / Lyxumia (lixisenatide)\, phase 4\, Type 2 Diabetes.\n
 Study: Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-
 world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Age
 nts\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/lixisenatide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07307235
URL:https://assetmemo.bio/drug/lixisenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07117240-128@assetmemo.bio
DTSTAMP:20261121T005618Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Adlyxin / Lyxumia (lixisenatide): Phase 4 readout est. (NCT07117240
 )
DESCRIPTION:Adlyxin / Lyxumia (lixisenatide)\, phase 4.\nStudy: Evaluation 
 of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-In
 duced Diabetes\nEstimated primary completion: 9 February 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/lixisenatide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07117240
URL:https://assetmemo.bio/drug/lixisenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
